<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863014</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-HTG-20118</org_study_id>
    <secondary_id>2021-000437-13</secondary_id>
    <nct_id>NCT04863014</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the proportion of patients with&#xD;
      triglycerides (TG) &gt;880 mg/dL, without familial chylomicronemia syndrome (FCS) due to loss of&#xD;
      function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia&#xD;
      (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after&#xD;
      treatment with evinacumab versus placebo.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To determine the change in the standard lipid profile after therapy with evinacumab&#xD;
           versus placebo&#xD;
&#xD;
        -  To determine the changes in specialty lipoprotein parameters (ApoC3, ApoB48, ApoB100,&#xD;
           and nuclear magnetic resonance [NMR] lipid profile) after therapy with evinacumab versus&#xD;
           placebo&#xD;
&#xD;
        -  To measure the number of AP episodes per patient&#xD;
&#xD;
        -  To assess the safety and tolerability of evinacumab&#xD;
&#xD;
        -  To assess the potential immunogenicity of evinacumab&#xD;
&#xD;
        -  To assess the concentrations of total evinacumab and total angiopoietin-like 3 (ANGPTL3)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">October 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with at least 1 positively adjudicated acute pancreatitis (AP) episode</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in ApoC3</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in fasting triglycerides (TGs)</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol (TC)</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in ApoB48</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in ApoB100 levels</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in nuclear magnetic resonance (NMR)-determined particle size and number</measure>
    <time_frame>Baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of independently adjudicated episodes of AP per patient</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>evinacumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized 1:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evinacumab</intervention_name>
    <description>Intravenous infusion every 4 weeks (Q4W)</description>
    <arm_group_label>evinacumab</arm_group_label>
    <other_name>REGN1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion Q4W</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Documented history of HTG-associated AP within 15 months of screening&#xD;
&#xD;
          2. Fasting serum TG value &gt;880 mg/dL (10 mmol/L) on 2 occasions at least 2 days apart&#xD;
             determined during the screening period.&#xD;
&#xD;
          3. Stable dose of lipid-lowering therapy (≥8 weeks) and willingness to maintain a stable&#xD;
             regimen throughout the study&#xD;
&#xD;
          4. Body mass index ≥18.0 and ≤40.0 kg/m2&#xD;
&#xD;
          5. Compliance with a stable diet and exercise regimen at screening and willingness to&#xD;
             continue the diet through the end of the study&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalization for AP within 4 weeks of screening&#xD;
&#xD;
          2. Known genetic FCS defined as homozygous or compound heterozygous LoF mutations in LPL&#xD;
             as defined in the protocol&#xD;
&#xD;
          3. Symptomatic gallstone disease within 6 months prior to screening as defined in the&#xD;
             protocol&#xD;
&#xD;
          4. Use of any medication or nutraceutical known to alter serum lipids which has not been&#xD;
             part of a stable therapeutic regimen for at least 8 weeks, and there are no plans to&#xD;
             change the regimen during the study&#xD;
&#xD;
          5. Presence of any clinically significant, uncontrolled endocrine disease known to&#xD;
             influence serum lipids as defined in the protocol&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/ Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe HTG</keyword>
  <keyword>Recurrent Acute Pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

